ClinicalTrials.gg
CompletedNCT02957630Updated Feb 5, 2018

"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"

A Phase 1/2 interventional study of 15 mg E4/3 mg DRSP and 30 mcg EE/150 mcg LNG in Contraception, Liver Metabolism and Hemostasis Parameter, sponsored by Estetra. Completed at 1 site in Netherlands. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-05.

Sponsored by Estetra · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The proposed study will provide an assessment of the effect of this combination on endocrine function, metabolic control and hemostasis during 6 treatment cycles. This will be compared to the effects of two reference COCs.

02

Conditions studied

  • Contraception
  • Liver Metabolism
  • Hemostasis Parameter

Keywords

  • Estetrol (E4)
  • Drospirenone (DRSP)
  • Ethinylestradiol (EE)
  • Levonorgestrel (LNG)
  • Oral contraceptive
  • Prevention of pregnancy
  • Hemostasis
  • Metabolism
03

In context

Lead sponsor

Estetra is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult woman
  • Negative pregnancy test at subject screening and randomization
  • Aged 18-50 years (inclusive) at the time of signing the ICF
  • Good physical and mental health on the basis of medical, surgical and gynecological history, physical examination, gynecological examination, clinical laboratory, , echocardiography and vital signs
  • from 18.0 to 30.0 kg/m², inclusive, at time of screening visit
  • Able to fulfil the requirements of the protocol and have indicated a willingness to participate in the study by providing written

Exclusion criteria

Exclusion Criteria:

  • Known to any of the product ingredients
  • Smoking if > 35 years old
  • Dyslipoproteinemia or use of antilipidemic agent
  • Known diabetes mellitus
  • Current use of antidiabetic drugs, including insulin
  • Arterial hypertension
  • Any condition associated with an increased risk of venous thromboembolism and/or arterial thromboembolism.
  • Any condition associated with abnormal uterine/vaginal bleeding.
  • Presence of an undiagnosed breast mass
  • Current symptomatic gallbladder disease
  • History of pregnancy- or COC-related cholestasis
  • Presence or history of severe hepatic disease
  • Presence or history of pancreatitis if associated with hypertriglyceridemia
  • Porphyria
  • Presence or history of benign liver tumors (focal nodular hyperplasia and hepatocellular adenoma)
  • Presence of renal impairment ( [GFR] \<60 mL/min/1.73m²)
  • Hyperkalemia or presence of conditions that predispose to hyperkalemia
  • Presence or history of hormone-related
  • History of non-hormone-related malignancy within 5 years before screening; subjects with a non-melanoma skin cancer are allowed in the study
  • Use of drugs potentially triggering interactions with COCs
  • History of alcohol or drug abuse within 12 months prior to screening
  • Presence or history of thyroid disorders
  • Participation in another investigational drug clinical study within 1 month (30 days) or have received an investigational drug within the last 3 months (90 days) prior to randomization. Subjects who participated in an oral clinical study using Food and Drug Administration (FDA)/European Union (EU) approved active ingredients, may be randomized 2 months (60 days) after completing the preceding study
  • Sponsor, contract research organization (CRO) or Principal Investigator's (PI's) site personnel directly affiliated with this study
  • Is judged by the PI to be unsuitable for any reason
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    15 mg E4/3 mg DRSP

    15 mg estetrol/3 mg drospirenone combined oral contraceptive

    Drug: 15 mg E4/3 mg DRSP

  • Active comparator
    30 mcg EE/150 mcg LNG

    30 mcg ethinylestradiol/150 mcg levonorgestrel combined oral contraceptive

    Drug: 30 mcg EE/150 mcg LNG

  • Active comparator
    20 mcg EE/3 mg DRSP

    20 mcg ethinylestradiol/3 mg drospirenone combined oral contraceptive

    Drug: 20 mcg EE/3 mg DRSP

Interventions

  • Drug15 mg E4/3 mg DRSP

    Drug pages: Estetrol · Drospirenone

    15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.

    Also known as: 15 mg estetrol and 3 mg drospirenone

  • Drug30 mcg EE/150 mcg LNG

    30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.

    Also known as: 30 mcg ethinylestradiol and 150 mcg levonorgestrel

  • Drug20 mcg EE/3 mg DRSP

    20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.

    Also known as: 20 mcg ethinylestradiol and 3 mg drospirenone

06

What researchers measure

Primary outcomes

  1. Plasma concentration of prothrombin fragment 1+2

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  2. Plasma concentration of APC resistance (ETP-based, APTT-based)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  3. Plasma concentration of D-dimer

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  4. Plasma concentration of factor VII

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  5. Plasma concentration of factor VIII

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  6. Plasma concentration of von Willebrand factor

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  7. Plasma concentration of factor II

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  8. Plasma concentration of antithrombin

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  9. Plasma concentration of free and total Protein S

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  10. Plasma concentration of protein C

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  11. Plasma concentration of plasminogen activator inhibitor type-1 (PAI-1)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  12. Plasma concentration of tissue type plasminogen activator (t-PA)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  13. Plasma concentration of plasminogen

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  14. Plasma concentration of free tissue factor pathway inhibitor (TPFI)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  15. Plasma concentration of E-selectin

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  16. Plasma concentration of fibrinogen

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  17. Serum concentration of insulin

    Time frame: At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for Cycles 3 and 6 (1 cycle = 28 days).

  18. Serum concentration of glucose

    Time frame: At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for Cycles 3 and 6 (1 cycle = 28 days).

  19. Serum concentration of C-peptide

    Time frame: At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for Cycles 3 and 6 (1 cycle = 28 days).

  20. Plasma concentration of glycated hemoglobin (HbA1c)

    Time frame: At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  21. Homeostasis Model Assessment - Insulin Resistance (HOMA-IR)

    Time frame: At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  22. Oral glucose tolerance test (OGTT)

    Time frame: At 0 (pre-glucose challenge), 30, 60, 90, 120 and 180 minutes after glucose challenge during pretreatment Cycle; at 0 (pre-glucose challenge), 30, 60, 90, 120 and 180 minutes after glucose challenge during Cycles 3 and 6 (1 cycle = 28 days).

  23. Serum concentration of prolactin

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  24. Serum concentration of follicle-stimulating hormone (FSH)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  25. Serum concentration of luteinizing hormone (LH)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  26. Serum concentration of estradiol (E2)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  27. Serum concentration of progesterone (P)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  28. Serum concentration of thyroïd stimulating hormone (TSH)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  29. Serum concentration of free thyroxine (fT3)/free triiodothyronine (fT4)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  30. Serum concentration of dihydroepiandrostenedione (DHEAS)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  31. Serum concentration of androstenedione

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  32. Serum concentration of total testosterone (T)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  33. Serum concentration of dihydrotestosterone (DHT)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  34. Serum concentration of total cortisol

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  35. Serum concentration of aldosterone

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  36. Serum concentration of high density lipoprotein (HDL)-cholesterol

    Time frame: At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  37. Serum concentration of low density lipoprotein (LDL)-cholesterol

    Time frame: At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  38. Serum concentration of total cholesterol

    Time frame: At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  39. Serum concentration of triglycerides

    Time frame: At screening, between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  40. Serum concentration of lipoprotein (a)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  41. Serum concentration of apoliporotein A1

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  42. Serum concentration of apoliporotein B

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  43. Serum concentration of C-reactive protein

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  44. Serum concentration of corticosteroid binding globulin (CBG)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  45. Serum concentration of sex hormone binding globulin (SHBG)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  46. Serum concentration of thyroxin binding globulin (TBG)

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

  47. Serum concentration of angiotensinogen

    Time frame: Between Days 18 and 21 for the pretreatment Cycle, and between Days 18 and 21 for the Cycles 3 and 6 (1 cycle = 28 days).

Secondary outcomes

  1. Number of subjects with adverse events as a measure of safety and tolerability

    Time frame: From up to 28 days before randomization to maximum Day 4 of the Cycle 7 (1 cycle = 28 days).

  2. Serum concentration of lactate dehydrogenase (LDH) 1 and 2

    Time frame: Between Days 18 and 21 for the pretreatment Cycle and between Days 18 and 21 for the Cycle 6 (1 cycle = 28 days)

  3. Serum concentration of tropinin T and I

    Time frame: Between Days 18 and 21 for the pretreatment Cycle and between Days 18 and 21 for the Cycle 6 (1 cycle = 28 days)

  4. Electrocardiogram (ECG) parameters

    The following ECG parameters will be recorded: heart rate, PR-interval, QRS-duration, QT-interval, QTc interval (Fridericias's)

    Time frame: At screening and between Days 18 and 21 for Cycle 6 (1 cycle = 28 days).

  5. Echocardiographic parameters

    Time frame: At screening and between Days 18 and 21 for Cycle 6 (1 cycle = 28 days).

  6. Change from baseline to end of treatment in the different items of the menstrual distress questionnaires (MDQ) form C

    Time frame: At pretreatment Cycle and between Days 18 and 21 for Cycle 6 (1 cycle = 28 days).

07

Study locations

1 site
  • Dinox BV
    Groningen, 9713 GZ, Netherlands
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Oct 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2016
First posted
Nov 8, 2016
Start
Sep 2016
Primary completionActual
Oct 9, 2017
CompletionActual
Oct 9, 2017
Last update
Feb 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02957630
Lead sponsor
Estetra
Responsible party
Sponsor
First posted
Nov 8, 2016
Start date
Sep 2016
Primary completion
Oct 9, 2017
Completion
Oct 9, 2017
Last update
Feb 5, 2018

Study contacts

Christine Klipping
principal investigator · Dinox BV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estetrol · Drospirenone

Start the discussion